Glyceryl trinitrate inhibits hypoxia-induced release of soluble fms-like tyrosine kinase-1 and endoglin from placental tissues

American Journal of Pathology

Volumn 178, Issue 6, 2011, Pages 2888-2896

  Barsoum, Ivraym B ^a   Renaud, Stephen J ^a,b   Graham, Charles H ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; ENDOGLIN; GLYCERYL TRINITRATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CHORION VILLUS; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EXPLANT; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOLOCALIZATION; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TERM BIRTH;

EID: 79959387433     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.02.013     Document Type: Article

References (49)

1. Redman CW, Sargent IL: Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594 (Pubitemid 40807500)
2. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y: Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003, 88:2348-2351 (Pubitemid 36549917)
3. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683 (Pubitemid 38364626)
4. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649 (Pubitemid 43865232)
5. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658 (Pubitemid 36278583)
6. Ahmad S, Ahmed A: Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004, 95:884-891 (Pubitemid 39435003)
7. Banks RE, Forbes MA, Searles J, Pappin D, Canas B, Rahman D, Kaufmann S, Walters CE, Jackson A, Eves P, Linton G, Keen J, Walker JJ, Selby PJ: Evidence for the existence of a novel pregnancyassociated soluble variant of the vascular endothelial growth factor receptor: Flt-1. Mol Human Reprod 1998, 4:377-386 (Pubitemid 28228534)
8. Tsatsaris V, Goffin F, Munaut C, Brichant J-F, Pignon M-R, Noel A, Schaaps J-P, Cabrol D, Frankenne F, Foidart J-M: Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003, 88:5555-5563 (Pubitemid 37452769)
9. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A: Uteroplacental ischemia results in proteinuric hypertension and elevated sFlt-1. Kidney Int 2007, 71:977-984 (Pubitemid 46741987)
10. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992, 267:19027
11. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y: Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007, 92:2672-2679 (Pubitemid 47037375)
12. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005 (Pubitemid 44343543)
13. Sandau KB, Zhou J, Kietzmann T, Brune B: Regulation of the hypoxiainducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J Biol Chem 2001, 276:39805-39811
14. Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, Post M, Caniggia I: Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005, 90:4299-4308 (Pubitemid 41058212)
15. Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T, Post M, Caniggia I: Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008, 172:77-85 (Pubitemid 351186370)
16. Zamudio S, Wu Y, Ietta F, Rolfo A, Cross A, Wheeler T, Post M, Illsley NP, Caniggia I: Human placental hypoxia-inducible factor-1α expression correlates with clinical outcomes in chronic hypoxia in vivo. Am J Pathol 2007, 170:2171-2179 (Pubitemid 47339288)
17. Nevo O, Soleymanlou N, Wu Y: Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006, 291:R1085
18. Rajakumar A, Powers R, Hubel C, Shibata E, von Versen-Hoynck F, Plymire D, Jeyabalan A: Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta 2009, 30:25-34
19. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995, 92:5510-5514
20. Semenza GL: Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007, 2007:cm8
21. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-alpha to the von Hippel- Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472 (Pubitemid 32335942)
22. Brune B, Zhou J: Nitric oxide and superoxide: interference with hypoxic signaling. Cardiovasc Res 2007, 75:275-282 (Pubitemid 46961919)
23. Hagen T, Taylor CT, Lam F, Moncada S: Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003, 302:1975-1978 (Pubitemid 37523507)
24. Frederiksen LJ, Sullivan R, Maxwell LR, Macdonald-Goodfellow SK, Adams MA, Bennett BM, Siemens DR, Graham CH: Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 2007, 13:2199-2206 (Pubitemid 46649890)
25. Frederiksen LJ, Siemens DR, Heaton JP, Maxwell LR, Adams MA, Graham CH: Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol 2003, 170:1003-1007 (Pubitemid 36999621)
26. Lowe DT: Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000, 4:441-458 (Pubitemid 30664037)
27. Belkacemi L, Bainbridge SA, Dickinson MA, Smith GN, Graham CH: Glyceryl trinitrate inhibits hypoxia/reoxygenation-induced apoptosis in the syncytiotrophoblast of the human placenta: therapeutic implications for preeclampsia. Am J Pathol 2007, 170: 909-920 (Pubitemid 47339360)
28. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart J-M: Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008, 23: 1407-1415 (Pubitemid 351770590)
29. Kishuku M, Nishioka Y, Abe S, Kishi J, Ogino H, Aono Y, Azuma M, Kinoshita K, Rentsenhand B, Makino H, Ranjan P, Minakuchi K, Sone S: Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property. J Immunol 2009, 183:8176-8185
30. Kendall RL, Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993, 90:10705-10709 (Pubitemid 23347111)
31. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, Post M: Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3), J Clin Inves 2000, 105:577-587 (Pubitemid 30146504)
32. Palacios-Callender M, Quintero M, Hollis VS, Springett RJ, Moncada S: Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase, Proc Natl Acad Sci U S A 2004, 101:7630-7635 (Pubitemid 38658080)
33. Jeyabalan A, McGonigal S, Gilmour C, Hubel C, Rajakumar A: Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia, Placenta 2008, 29:555-563
34. Gu Y, Lewis DF, Wang Y: Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies, J Clin Endocrinol Metab 2008, 93:260-266
35. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R: PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008, 87:837-842
36. Cindrova-Davies T: Gabor Than Award Lecture 2008: Pre-eclampsia - from placental oxidative stress to maternal endothelial dysfunction, Placenta 2009, 30:55-65
37. Burton GJ, Jauniaux E: Placental oxidative stress: from miscarriage to preeclampsia, J Soc Gynecol Investig 2004, 11:342-352 (Pubitemid 39185874)
38. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E: Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Human Reprod 2001, 7:205-210 (Pubitemid 32148349)
39. Saito S, Sakai M: Th1/Th2 balance in preeclampsia. J Reprod Immunol 2003, 59:161-173 (Pubitemid 36945234)
40. Raghupathy R, Makhseed M, Azizieh F, Hassan N, Al-Azemi M, Al-Shamali E: Maternal Th1- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. Cell Immunol 1999, 196:122-130 (Pubitemid 29496461)
41. Royle C, Lim S, Xu B, Tooher J, Ogle R, Hennessy A: Effect of hypoxia and exogenous IL-10 on the pro-inflammatory cytokine TNF-alpha and the anti-angiogenic molecule soluble Flt-1 in placental villous explants. Cytokine 2009, 47:56-60
42. Xu B, Thornton C, Tooher J, Hennessy A: Exogenous soluble VEGF receptor-1 (sFlt-1) regulates Th1/Th2 cytokine production from normal placental explants via intracellular calcium. Hypertens Pregnancy 2009, 28:448-456
43. Duley L, Meher S, Abalos E: Management of pre-eclampsia. BMJ 2006, 332:463-468 (Pubitemid 43342046)
44. Roberts DJ, Post MD: The placenta in pre-eclampsia and intrauterine growth restriction. J Clin Pathol 2008, 61:1254-1260
45. Xu B, Thornton C, Tooher J, Ogle R, Lim S, Makris A, Hennessy A: Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin Exp Pharmacol Physiol 2009, 36:839-842
46. Cacciatore B, Halmesmaki E, Kaaja R, Teramo K, Ylikorkala O: Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1998, 179:140-145 (Pubitemid 28394487)
47. Grunewald C, Kublickas M, Carlstrom K, Lunell N, Nisell H: Effects of nitroglycerin on the uterine and umbilical circulation in severe preeclampsia. Obstet Gynecol 1995, 86:600-604
48. Cetin A, Yurtcu N, Guvenal T, Imir A, Duran B, Cetin M: The effect of glyceryl trinitrate on hypertension in women with severe preeclampsia. HELLP syndrome, and eclampsia. Hypertens Pregnancy 2004, 23:37-46 (Pubitemid 38445551)
49. Lees C, Valensise H, Black R, Harrington K, Byiers S, Romanini C, Campbell S: The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of pre-eclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol 1998, 12:334-338 (Pubitemid 28517638)